INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,373,068 | -24.6% | 326,921 | 0.0% | 0.37% | 0.0% |
| Q2 2023 | $1,820,950 | +36.0% | 326,921 | +39.9% | 0.37% | +5.5% |
| Q1 2023 | $1,339,261 | +453.4% | 233,728 | +1.4% | 0.35% | +452.4% |
| Q4 2022 | $242,025 | -86.3% | 230,500 | -65.1% | 0.06% | -85.0% |
| Q3 2022 | $1,772,000 | -44.1% | 661,144 | -0.6% | 0.42% | -52.3% |
| Q2 2022 | $3,172,000 | +163.0% | 664,980 | +125.4% | 0.88% | +171.9% |
| Q1 2022 | $1,206,000 | -41.6% | 294,980 | -2.5% | 0.32% | -13.8% |
| Q4 2021 | $2,064,000 | -44.5% | 302,615 | -5.6% | 0.38% | -34.8% |
| Q3 2021 | $3,717,000 | – | 320,724 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |